Sign in
CompletedNo phase

Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study

Key facts

Who runs it
Avelo AG
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
23 people enrolled
Started
13 Nov 2024
Ended
21 May 2025
Type of study
Observational
Treatments tested
  • Sputum collection for molecular analysis
  • Breath and cough collection for molecular analysis
Record updated
8 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Able to understand the scope of the study and provide written informed consent
  • Age >18 years
  • Speaking German or English
  • Health status (assessed by study personnel at local site) well enough to use the breath collection devices
  • Willing to provide all three study samples (sputum and two breath samples) required for the study
  • Clinical diagnosis of a lower respiratory tract infection (LRTI) defined as:; (i) New infiltrate (chest X-ray, ultrasound, or CT scan), and (ii) at least one clinical symptom suggestive of LRTI (fever ≥38°C, chills, new or worsening cough, new or worsening sputum production, new or worsening dyspnea, tachypnoea, chest pain)

Who cannot take part

  • Hospitalization within the last 14 days prior to admission
  • Patients for whom the collection of all three study specimens within 48 hours of initiating antibiotic treatment is not feasible
  • Patients with known cystic fibrosis or bronchiectasis
  • Critically ill patients at the discretion of the investigator
  • Patients on oxygen supplementation with a face mask, high-flow-oxygen, non-invasive or mechanical ventilation; oxygen supplementation via nasal cannula will be permitted
  • Patients with proven acute pulmonary embolism
  • Patients with best supportive care
  • Patients with severe hypoxemia (SpO2 <88%) despite oxygen supplementation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will assess the performance of two novel breath collection devices and their subsequent detection of respiratory pathogens compared to sputum samples in patients with lower respiratory tract infections.

Treatments tested

  • Sputum collection for molecular analysis
  • Breath and cough collection for molecular analysis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study (Acronym: AeroCAP)
Record updated
8 August 2025